Another promising combination is using both anti-PD-1 and anti-CTLA-4 antibodies, which together enhance the immune response by reducing the number of immunosuppressive cells (MDSCs) in the TME, helping the immune system to target the tumor more effectively [74] (Fig. 10). Here, CTLA4 is linked to neoplasm.